Compounded semaglutide formulations are not FDA-approved, but licensed providers may prescribe them when medically appropriate
This work is supported by the National Key Research & Development Program (2022YFC2603900), Beijing Natural Science Foundation (JQ24055), and the National Natural Science Foundation of China (22175189, 52373127)
High inflammation in tumors has been shown to be associated with increased survival in almost all cancer patients ( 3.1.4 Tumor-associated macrophages (TAMs) TAMs promote cancer growth and metastasis by secreting growth factors, cytokines, and proteases, and they also promote chronic inflammation by releasing mediators such as TNF, TGF-, IL-6, and IL-12
Patients taking semaglutide without experiencing symptoms should continue as instructed and discuss any questions with their primary care physician
The rationale lies in its influence on neurotransmitter systems involved in memory and cognitive function